Cover Image
市場調查報告書

更年期的心血管舒縮症狀 : 開發平台分析

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257799
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
更年期的心血管舒縮症狀 : 開發平台分析 Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 62 Pages
簡介

所謂更年期的血管舒縮症狀是指熱潮紅、盜汗等接近皮膚表面的血管突然擴張而引起的症狀,一般是由於更年期及停經週邊期荷爾蒙變動造成的,但也可能因為其他因素如給藥、雌激素枯竭、甲狀腺疾病、糖尿病、多汗、焦慮症及恐慌症、肥胖、荷爾蒙活性型腫瘤、慢性感染疾病及神經病變等造成。

本報告提供更年期的心血管舒縮症狀的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

更年期的心血管舒縮症狀概要

治療藥的開發

  • 開發中產品:概要

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

開發治療藥的企業

  • Amgen Inc.
  • EndoCeutics, Inc.
  • Euroscreen S.A.
  • MenoGeniX, Inc.
  • Mithra Pharmaceuticals S.A.
  • Pherin Pharmaceuticals, Inc.
  • Pivot Pharmaceuticals Inc
  • Radius Health, Inc.
  • TherapeuticsMD, Inc.

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8831IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2016, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 2 respectively.

Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vasomotor Symptoms of Menopause (Hot Flashes) Overview
  • Therapeutics Development
  • Pipeline Products for Vasomotor Symptoms of Menopause (Hot Flashes) - Overview
    • Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics under Development by Companies
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Products under Development by Companies
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development
    • EndoCeutics Inc
    • MenoGeniX Inc
    • Mithra Pharmaceuticals SA
    • NeRRe Therapeutics Ltd
    • Ogeda SA
    • Pherin Pharmaceuticals Inc
    • Radius Health Inc
    • TherapeuticsMD Inc
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (acolbifene hydrochloride + prasterone) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (estradiol acetate + progesterone) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESN-364 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Estetrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBN-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MNGX-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PH-80HF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Q-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RAD-1901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR
      • Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes
      • Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
      • Apr 01, 2016: Radius to provide an update on RAD1901 at the ENDO 2016 Annual Meeting
      • Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate
      • Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes
      • Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection
      • Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting
      • Jun 19, 2010: Radius Presents Positive Phase IIa Study Results Of RAD1901 In Reducing Menopausal Hot Flashes
      • Jun 08, 2008: Radius Presents Preclinical Study Of RAD1901 At The Endocrine Society 2007 Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by NeRRe Therapeutics Ltd, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Radius Health Inc, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects, H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects (Contd..1), H2 2016
  • Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top